1 Min Read
* U.S. UNIT SUBMITTED NDA TO FDA ON SEPT. 28, TO SEEK MARKETING APPROVAL FOR RBP-7000, INDIVIOR’S TREATMENT OF SCHIZOPHRENIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.